Nuvig Therapeutics’ $47 Million Series A Financing

Goodwin advised Nuvig Therapeutics on the deal.

Nuvig Therapeutics announced its $47 million Series A financing and the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function.

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following in?ammation, and improve the treatment options for patients.

The round was led by Novo Holdings A/S and Platanus, and joined by Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.

The Goodwin team was led by Steven Green (Picture), Kingsley Taft, Mulon Luo, Carolyn Nguyen, Jacob Osborn, and Godze Guckaya.

Involved fees earner: Steven Green – Goodwin Procter; Gozde Guckaya – Goodwin Procter; Mulon Luo – Goodwin Procter; Carolyn Nguyen – Goodwin Procter; Jacob Osborn – Goodwin Procter; Kingsley Taft – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Nuvig Therapeutics;

Martina Bellini

Author: Martina Bellini